Jefferies Reiterates Buy Rating on Nektar Therapeutics (NKTR)

Jefferies analyst Roger Song reiterated a Buy rating and $121.00 price target on Nektar Therapeutics (NASDAQ: NKTR).

The analyst comments "We caught up with mgmt. We see Ph2b achieved key goals - confirming good safety, matching efficacy vs. low dose Olumiant with potential to beat, learning protocol nuances, selecting Ph3 dosing, and supported high likelihood of first "clean/ efficacious biologic" for AA pts that could expand market opportunity by being used in 1L and even less severe pts vs. JAKi. We like set-up into next year long-term data from AD and AA which likely drive upside potential."

For an analyst ratings summary and ratings history on Nektar Therapeutics click here. For more ratings news on Nektar Therapeutics click here.

Shares of Nektar Therapeutics closed at $49.16 yesterday.

You May Also Be Interested In

• William Blair Upgrades Moderna (MRNA) to Outperform, 'we believe Moderna has a clear line of sight to revenue diversification from the COVID business
• Dollar Tree climbs after Jefferies upgrades stock on improving traffic
• Bernstein SocGen Group Reiterates Outperform Rating on Linde (LIN), 'we see this sell-off as a major overreaction'